In pediatric patients with anti-TNF-refractory UC who achieve remission on ustekinumab, does duration of remission differ between those previously treated with vedolizumab and those treated with anti-TNF alone

What is known

- The one pediatric anti-TNF–refractory UC study reports that 9/10 children achieved steroid-free clinical remission on ustekinumab over a median 56-week follow-up. ¹

What is unknown / caveats

- No excerpt addresses whether remission duration on ustekinumab differs by prior vedolizumab exposure versus anti-TNF only in pediatric UC. - That single pediatric study does not stratify or compare outcomes by prior vedolizumab exposure.

## References

1. Rehman R, Riaz MS, Esharif D, Has P, Herzlinger M, Shapiro J, Subedi S. Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing. Intest Res. 2024. PMID: 38311714.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._